Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -10% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter...
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO,...
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter...
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -466.67% and 2.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended...
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO,...
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -45.45% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.